CurrentCignaPolicy IP0677

Cibinqo Prior Authorization Policy

Cigna coverage policy specifying prior authorization requirements, coverage criteria, and exclusions for Cibinqo (abrocitinib tablets) for treatment of atopic dermatitis in eligible patients aged ≥12 years.

Policy Summary

PayerCigna

PolicyCibinqo Prior Authorization Policy

Policy CodePolicy IP0677

Change TypeAnnual Revision (material updates)

Effective DateJun 1, 2025

Next Review DateN/A

Key ActionObtain prior authorization; initial approvals are for 3 months and continuation approvals for patients already on therapy ≥90 days are for 1 year when clinical benefit is documented.

SourceLink

POLICY UPDATE CHANGES

Ebglyss (lebrikizumab-lbkz) and Nemluvio (nemolizumab-ilto) were added to examples of systemic therapies and to examples of biologic immunomodulators not allowed concurrently with Cibinqo.

COVID-19 was removed from Conditions Not Covered.

≥12minimum approved patient age for coverage

3 moinitial approval duration

1 yrcontinuation approval duration

Not coveredconcurrent use with biologics/JAKis/immunosuppressants

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Cibinqo (abrocitinib)

FDA-Approved Indication

Covered when ALL of the following are met

Initial Therapy: Patient is ≥ 12 years of age; AND patient has had a 4-month trial of at least ONE systemic therapy OR patient tried at least ONE systemic therapy but was unable to tolerate a 4-month trial; AND medication is prescribed by or in consultation with an allergist, immunologist, or dermatologist.3 months approval

Examples of systemic therapies include dupilumab, lebrikizumab, nemolizumab, tralokinumab, methotrexate, azathioprine, cyclosporine, and mycophenolate mofetil.

Continuation Therapy (Currently Receiving): Patient has already received ≥ 90 days of therapy with Cibinqo; AND patient experienced a beneficial clinical response (improvement from baseline in at least one sign such as estimated body surface area affected, erythema, induration/papulation/edema, excoriations, lichenification, or decreased requirement for other therapies); AND compared with baseline the patient experienced improvement in at least one symptom (e.g., decreased itching).1 year approval

Cibinqo (abrocitinib) is considered not medically necessary for any indication other than treatment of atopic dermatitis. Explicit exclusions include concurrent administration with biologic therapies, concurrent use with other Janus kinase inhibitors (JAKis), and concurrent use with other potent immunosuppressants (for example, azathioprine or cyclosporine).

Concurrent administration of Cibinqo with the following is not medically necessary and will be denied: biologic immunomodulators (examples: dupilumab, tralokinumab, lebrikizumab, nemolizumab, and others listed in the policy), other JAK inhibitors (for example, upadacitinib, tofacitinib, baricitinib), and other potent immunosuppressants (for example, azathioprine, cyclosporine).

Initial Therapy

Initial approval when ALL of the following are met

Initial Approval: Patient is ≥ 12 years of age; AND patient has had a 4-month trial of at least ONE systemic therapy; OR patient tried at least ONE systemic therapy but was unable to tolerate a 4-month trial; AND medication is prescribed by or in consultation with an allergist, immunologist, or dermatologist.

Step	Requirement	Duration / Notes
1	Trial of at least one systemic therapy (examples: biologics such as dupilumab, lebrikizumab, nemolizumab, tralokinumab; or traditional systemics such as methotrexate, azathioprine, cyclosporine, mycophenolate mofetil).	4-month trial required, or documented intolerance to a 4-month trial.
Exception	Patient already receiving Cibinqo (continuation) or patient unable to tolerate a 4‑month systemic trial.	Patients currently receiving Cibinqo follow continuation criteria (see policy); initial approvals are 3 months when criteria met.
Prescriber requirement	Medication must be prescribed by or in consultation with an allergist, immunologist, or dermatologist.	Documentation of specialist prescriber or consultation required with prior authorization request.

Continuation Therapy

Continuation approval for patients already on therapy when ALL of the following are met

Continuation: Patient has received ≥ 90 days of Cibinqo therapy; AND there is documentation of a beneficial clinical response defined as improvement from baseline in at least one sign (estimated body surface area affected, erythema, induration/papulation/edema, excoriations, lichenification, or decreased need for other therapies); AND compared with baseline the patient experienced improvement in at least one symptom (e.g., decreased itching).

Minimum prior Cibinqo exposure for continuation

Minimum prior Cibinqo exposurePatient has already received at least 90 days (≥90 days) of therapy with Cibinqo

Patients with <90 daysPatients who have received <90 days of therapy or who are restarting should be considered under Initial Therapy

Continuation approval duration

Coding and Prior Therapy Durations

Duration of prior systemic therapy trial

Required systemic therapy trial durationPatient has had a 4-month trial of at least ONE systemic therapy

Intolerance alternativeOr patient tried at least ONE systemic therapy but was unable to tolerate a 4-month trial

Examples of systemic therapiesIncludes biologics (dupilumab, lebrikizumab, nemolizumab, tralokinumab) and traditional systemics (methotrexate, azathioprine, cyclosporine, mycophenolate mofetil)

Provider Actions and Authorization Requirements

Prior Authorization

Prior Authorization Required

Prior Authorization is required for Cibinqo. Initial approvals for new starts are for 3 months; continuation approvals for current patients are for 1 year. In cases where the approval is authorized in months, 1 month = 30 days. Initial authorization requires that Cibinqo be prescribed by or in consultation with a physician who specializes in the condition being treated (allergist, immunologist, or dermatologist).

Initial approvals: 3 months (new starts)
Continuation approvals: 1 year (current patients)
Prescriber requirement: specialist or documented consultation (allergist, immunologist, or dermatologist)

Step Therapy

Systemic Therapy Trial Required Prior to Cibinqo

Requests for Cibinqo will be denied if the patient has not had a trial of at least one systemic therapy for 4 months, unless the patient tried a systemic therapy but was unable to tolerate a 4-month trial. Examples of acceptable systemic therapies include biologics (e.g., dupilumab, tralokinumab, lebrikizumab, nemolizumab) and traditional systemics (e.g., methotrexate, azathioprine, cyclosporine, mycophenolate mofetil).

Definitions

Atopic dermatitis (AD): definition and context for systemic therapy

Definition of atopic dermatitis (AD)Inflammatory skin condition that may require systemic therapy when moderate to severe, widespread, or refractory to topical treatments

Clinical context for systemic therapySystemic therapies are recommended for moderate to severe or widespread disease, impaired quality of life, or disease refractory to topical therapies

Role of CibinqoCibinqo (abrocitinib) is an oral JAK inhibitor indicated for refractory moderate to severe atopic dermatitis in patients ≥12 years when disease not adequately controlled with other systemic agents or when such therapies are not advisable

Prescribing considerationsCibinqo is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or other immunosuppressants

Background

Cibinqo (abrocitinib) is an oral Janus kinase inhibitor (JAKi) indicated for moderate to severe atopic dermatitis in patients aged ≥ 12 years whose disease is not adequately controlled with other systemic therapies or when such therapies are not advisable.

Site of Care and Administration

Note

Ensure dose, frequency, duration, and site of care are clinically appropriate

When coverage is available and medically necessary, the dosage, frequency, duration of therapy, and site of care should be reasonable, clinically appropriate, and supported by evidence-based literature.